Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.

Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
复制标题

DOI:
10.1016/j.ymgme.2011.02.006
复制
发表时间:
2011-06
影响因子:
3.8
通讯作者:
Bali, Deeksha S.
Bali, Deeksha S.
中科院分区:
生物学2区
文献类型:
--
作者:
Koeberl, Dwight D.;Luo, Xiaoyan;Sun, Baodong;McVie-Wylie, Alison;Dai, Jian;Li, Songtao;Banugaria, Suhrad G.;Chen, Y. -T.;Bali, Deeksha S.

文献摘要

参考文献

被引文献

相似文献

Enzyme replacement therapy (ERT) with acid α-glucosidase has become available for Pompe disease; however, the response of skeletal muscle, as opposed to the heart, has been attenuated. The poor response of skeletal muscle has been attributed to the low abundance of the cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle compared to heart. To further understand the role of CI-MPR in Pompe disease, muscle-specific CI-MPR conditional knockout (KO) mice were crossed with GAA-KO (Pompe disease) mice. We evaluated the impact of CI-MPR-mediated uptake of GAA by evaluating ERT in CI-MPR-KO/GAA-KO (double KO) mice. The essential role of CI-MPR was emphasized by the lack of efficacy of ERT as demonstrated by markedly reduced biochemical correction of GAA deficiency and of glycogen accumulations in double KO mice, in comparison with administration of the same therapeutic doses in GAA-KO mice. Clenbuterol, a selective β2-agonist, enhanced CI-MPR expression in skeletal tissue and also increased efficacy from GAA therapy, thereby confirming the key role of CI-MPR with regard to enzyme replacement therapy in Pompe disease. Biochemical correction improved in both muscle and non-muscle tissues, indicating that therapy could be similarly enhanced in other lysosomal storage disorders. In summary, enhanced CI-MPR expression might improve the efficacy of enzyme replacement therapy in Pompe disease through enhancing receptor-mediated uptake of GAA.
DOI: 10.1152/ajpendo.2002.282.1.e31
发表时间: 2002-01-01
影响因子: 5.1
作者:
Awede, BL;Thissen, JP;Lebacq, J
通讯作者: Lebacq, J
DOI: 10.1016/j.ymthe.2004.09.017
发表时间: 2005-01-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Raben, N;Fukuda, T;Plotz, PH
通讯作者: Plotz, PH
DOI: 10.1097/00125817-200103000-00008
发表时间: 2001-03-01
影响因子: 8.8
作者:
Amalfitano, A;Bengur, AR;Chen, YT
通讯作者: Chen, YT
DOI: 10.1023/b:boli.0000031101.12838.c6
发表时间: 2004-01-01
影响因子: 4.2
作者:
Desnick, RJ
通讯作者: Desnick, RJ
DOI: 10.1016/s1097-2765(00)80155-0
发表时间: 1998-11-01
期刊: MOLECULAR CELL
影响因子: 16
作者:
Bruning, JC;Michael, MD;Kahn, CR
通讯作者: Kahn, CR